Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
News & Events
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU
News Category:
Regulatory news
Date:
06/01/2021
The European Medicines Agency (EMA) has
recommended
granting a conditional marketing authorisation for COVID-19 Vaccine Moderna to prevent coronavirus disease 2019 (COVID-19) in people from 18 years of age. This is the second COVID-19 vaccine that the EMA has recommended for authorisation.
The EMA’s human medicines committee (CHMP) has thoroughly assessed the data on the quality, safety and efficacy of the vaccine and recommended by consensus a formal conditional marketing authorisation be granted by the European Commission. This will assure EU citizens that the vaccine meets EU standards and puts in place the safeguards, controls and obligations to underpin EU-wide vaccination campaigns.
View EMA Press Release
The CHMP incorporates scientific expertise from all the national competent authorities in Europe, including the HPRA.
Further information
The
product information
approved by the CHMP for COVID-19 Vaccine Moderna contains prescribing information for healthcare professionals, a package leaflet for members of the public and details of conditions of the vaccine’s authorisation.
More information is also available in an
overview of the vaccine
in lay language, including a description of the vaccine’s benefits and risks, and why the EMA recommended its authorisation in the EU.
« Back
Date Printed: 18/04/2024